Mette Kirstine Agger's most recent trade in Lexeo Therapeutics Inc. was a trade of 18,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 25, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Lexeo Therapeutics Inc. | Mette Kirstine Agger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
scPharmaceuticals Inc | Mette Kirstine Agger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 19,750 | 19,750 | - | - | Stock Option (Right to Buy) | |
Lexeo Therapeutics Inc. | Kirstine Mette Agger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2024 | 36,000 | 36,000 | - | - | Stock Option (right to buy) | |
scPharmaceuticals Inc | Mette Kirstine Agger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,300 | 17,300 | - | - | Stock Option (Right to Buy) | |
scPharmaceuticals Inc | Mette Kirstine Agger | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 6,124 | 6,124 | - | - | Stock Option (Right to Buy) |